Thiopurine Dose in Intermediate and Normal Metabolizers of Thiopurine Methyltransferase May Differ Three-Fold

Clinical Gastroenterology and Hepatology

Volumn 6, Issue 6, 2008, Pages 654-660

  Gardiner, Sharon J ^a   Gearry, Richard B ^a   Begg, Evan J ^a   Zhang, Mei ^a   Barclay, Murray L ^a  

^a CHRISTCHURCH HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; MERCAPTOPURINE; THIOPURINE METHYLTRANSFERASE;

ABDOMINAL PAIN; ADULT; ARTICLE; DISEASE ACTIVITY; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG METABOLISM; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENTERITIS; FEMALE; FLU LIKE SYNDROME; GENOTYPE; HEADACHE; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; NAUSEA; PANCREATITIS; VOMITING;

6-MERCAPTOPURINE; ADULT; AZATHIOPRINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; MALE; METHYLTRANSFERASES; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 44749084416     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2008.02.032     Document Type: Article

References (33)

1. Sandborn W., Sutherland L., Pearson D., et al. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2 (2000) CD000545
2. Gearry R.B., Barclay M.L., Burt M.J., et al. Thiopurine drug adverse effects in a population of New Zealand patients with inflammatory bowel disease. Pharmacoepidemiol Drug Saf 13 (2004) 563-567
3. Pearson D.C., May G.R., Fick G.H., et al. Azathioprine and 6-mercaptopurine in Crohn disease: a meta-analysis. Ann Intern Med 123 (1995) 132-142
4. Gardiner S.J., and Begg E.J. Pharmacogenetics testing for drug metabolizing enzymes-is it happening in practice?. Pharmacogenet Genomics 15 (2005) 365-369
5. Schaeffeler E., Fischer C., Brockmeier D., et al. Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants. Pharmacogenetics 14 (2004) 407-417
6. Weinshilboum R.M., and Sladek S.L. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 32 (1980) 651-662
7. Evans W.E., Horner M., Chu Y.Q., et al. Altered mercaptopurine metabolism, toxic effects and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia. J Pediatr 119 (1991) 985-989
8. Lennard L., Gibson B.E., Nicole T., et al. Congenital thiopurine methyltransferase deficiency and 6-mercaptopurine toxicity during treatment for acute lymphoblastic leukaemia. Arch Dis Child 69 (1993) 577-579
9. Kaskas B.A., Louis E., Hindorf U., et al. Safe treatment of thiopurine S-methyltransferase deficient Crohn's disease patients with azathioprine. Gut 52 (2003) 140-142
10. Gardiner S.J., Gearry R.B., Barclay M.L., et al. Two cases of TPMT deficiency-a lucky save and a near miss with azathioprine. Br J Clin Pharmacol 62 (2006) 473-476
11. Lennard L., van Loon J., Lilleyman J.S., et al. Thiopurine pharmacogenetics in leukemia: correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations. Clin Pharmacol Ther 41 (1987) 18-25
12. Lennard L., Lilleyman J.S., Van Loon J., et al. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 336 (1990) 225-229
13. Sanderson J., Ansari A., Marinaki T., et al. Thiopurine methyltransferase: should it be measured before commencing thiopurine drug therapy?. Ann Clin Biochem 41 (2004) 294-302
14. Lichtenstein G.R. Monitoring 6-mercaptopurine/azathioprine metabolite levels. Am J Gastroenterol 102 (2007) S14-S17
15. Meggitt S.J., Gray J.C., and Reynolds N.J. Azathioprine dosed by thiopurine methyltransferase activity for moderate-to-severe atopic eczema: a double-blind, randomised controlled trial. Lancet 367 (2006) 839-846
16. Tan B.B., Lear J.T., Gawkrodger D.J., et al. Azathioprine in dermatology: a survey of current practice in the U.K. Br J Dermatol 136 (1997) 351-355
17. Fargher E.A., Tricker K., Newman W., et al. Current use of pharmacogenetic testing: a national survey of thiopurine methyltransferase testing prior to azathioprine prescription. J Clin Pharm Ther 32 (2007) 187-195
18. Gearry R.B., Richardson A., Frampton C.M.A., et al. High incidence of Crohn's disease in Canterbury, New Zealand: results of an epidemiological study. Inflamm Bowel Dis 12 (2006) 936-943
19. Irvine E.J., Zhou Q., and Thompson A.K. The short inflammatory bowel disease questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. Am J Gastroenterol 91 (1996) 1571-1578
20. Sandborn W.J. A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine and methotrexate. Am J Gastroenterol 91 (1997) 423-433
21. Gearry R.B., Barclay M.L., Roberts R.L., et al. Thiopurine methyltransferese and 6-thioguanine nucleotide measurement: early experience of use in clinical practice. Intern Med J 35 (2005) 580-585
22. Gardiner S.J., Gearry R.B., Roberts R.L., et al. Exposure to thiopurine drugs through breast milk is low based on metabolite concentrations in mother-infant pairs. Br J Clin Pharmacol 62 (2006) 453-456
23. Sies C., Florkowski C.M., George P.M., et al. Measurement of thiopurine methyl transferase activity guides does-initiation and prevents toxicity from azathioprine. N Z Med J 118 (2005) 1210
24. Weinshilboum R.M., Raymond F.A., and Pazmino P.A. Human erythrocyte thiopurine methyltransferase: radiochemical microassay and biochemical properties. Clin Chim Acta 85 (1978) 323-333
25. Roberts R.L., Barclay M.L., Gearry R.B., et al. A multiplexed allele-specific polymerase chain reaction assay for the detection of common thiopurine S-methyltransferase (TPMT) mutations. Clin Chim Acta 341 (2004) 49-53
26. Osterman M.T., Kundu R., Lichtenstein G.R., et al. Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology 130 (2006) 1047-1053
27. Schutz E., Gummert J., Mohr F.W., et al. Should 6-thioguanine nucleotides be monitored in heart transplant recipients given azathioprine?. Ther Drug Monit 18 (1996) 228-233
28. de Boer N.K.H., Mulder D.J.J., and Van Bodegraven A.A. Nodular regenerative hyperplasia and thiopurines: the case for level-dependent toxicity. Liver Transplantation 11 (2005) 1300-1301
29. Dubinsky M.C., Vasiliauskas E.A., Singh H., et al. 6-Thioguanine can cause serious liver injury in inflammatory bowel disease patients. Gastroenterology 125 (2003) 298-303
30. Dassopoulos T. Pharmacogenomics of IBD therapies. Gastroenterol Hepatol 3 (2007) 338-339
31. Cuffari C. A physician's guide to azathioprine metabolite testing. Gastroenterol Hepatol 2 (2006) 58-63
32. Lichtenstein G.R., Abreu M.T., Cohen R., et al. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 130 (2006) 940-987
33. Gisbert J.P., Gonzalez-Lama Y., and Mate J. Thiopurine-induced liver injury in patients with inflammatory bowel disease: a systematic review. Am J Gastroenterol 102 (2007) 1518-1527